Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Advantest Corp. (ATEYY - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Advantest has a trailing twelve months PE ratio of 14.4, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 16.6x. If we focus on the long-term PE trend, Advantest’s current PE level puts it below its midpoint over the past five years, with the number having risen rapidly over the past few months.
Further, the stock’s PE also compares favorably with the broader industry’s trailing twelve months PE ratio, which stands at 30.1. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that Advantest has a forward PE ratio (price relative to this year’s earnings) of just 9.2, so it is fair to say that a slightly more value-oriented path may be ahead for Advantest stock in the near term too.
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, Advantest has a P/S ratio of about 1.9. This is a bit lower than the S&P 500 average, which comes in at 3x right now. Also, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.
If anything, ATEYY is in the lower end of its range in the time period from a P/S metric, suggesting some level of undervalued trading—at least compared to historical norms.
Broad Value Outlook
In aggregate, Advantest currently has a Value Score of B, putting it into the top 40% of all stocks we cover from this look. This makes Advantest a solid choice for value investors.
What About the Stock Overall?
Though Advantest might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of B and a Momentum Score of B. This gives ATEYY a Zacks VGM score — or its overarching fundamental grade — of B. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been upbeat. The current quarter has seen one estimate go higher in the past sixty days, while the full year estimate has also seen one up in the same time period.
This has had just a small impact on the consensus estimate though as the current quarter consensus estimate has risen by 104.5% in the past two months, while the full year estimate has increased 33.7%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
Advantest Corp. Price and Consensus
This positive trend signifies bullish analyst sentiment, and its Zacks Rank #2 (Buy) indicates robust fundamentals and expectations of outperformance in the near term.
Advantest is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Further, a strong industry rank (among Top 15% of more than 250 industries) instills our confidence. In fact, over the past two years, the broader industry has clearly outperformed the market at large, as you can see below:
So, it might pay for value investors to delve deeper into the company’s prospects, as fundamentals indicate that this stock could be a compelling pick.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>